Strategic investors are backing US-based spinal care company Baxano in its $30m series C round. US venture capital firm CMEA Capital, which includes healthcare companies Johnson & Johnson and Pfizer as its corporate partners, led the C round for Baxano. Kaiser Permanente Ventures, the corporate venturing division of US healthcare company Kaiser Permanente, also invested along with VCs Affinity Capital Management, Prospect Venture Partners, Three Arch Partners and Kearny Venture Partners. Baxano previously raised $20m in its series B round in 2008 and $8.6m series A the year before.